Fuxiang Pharmaceutical (300497.SZ): “Artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced

Gelonghui, May 11 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that “artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced. In addition, the company's microbial protein can also be widely used in protein drinks, health foods, specialty foods, pet food, etc., and has characteristics such as high protein, high dietary fiber, low sugar, low fat, zero cholesterol, zero trans fatty acids, etc., and has been tested to contain 18 kinds of amino acids needed by the human body.

Gelonghui FinanceMay 11 02:36 ET

Fuxiang Pharmaceutical (300497.SZ): Currently building its own multi-functional synthetic bio-biological fermentation production line

Gelonghui, May 9 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline that uses renewable biomass as raw materials and organisms as production media to transform or create artificial life systems. Synthetic biology has characteristics such as being clean, efficient, and renewable. It has the potential to completely disrupt the current pattern at both the level of technology and industrial innovation, and is an important development direction for the company. Currently, the company has built its own multi-functional synthetic bio-biological fermentation production line, and has accumulated deep experience in biological fermentation technology, which is mainly used in the fields of medicine and food. The company's various enzyme preparations, hydroxyproline

Gelonghui FinanceMay 8 19:49 ET

Fuxiang Pharmaceutical (300497.SZ): Actual controller Bao Jianhua completed an increase of 2.351,000 shares

Gelonghui, May 7 | Fuxiang Pharmaceutical (300497.SZ) announced that as of the announcement date, Mr. Bao Jianhua, the controlling shareholder, actual controller and chairman of the company, had increased his holdings by 2.351,000 shares through centralized bidding, to an increase of 25.134,400 yuan. His current holdings increase plan has been completed.

Gelonghui FinanceMay 7 05:30 ET

There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 26% Price Jump

Despite an already strong run, Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) shares have been powering on, with a gain of 26% in the last thirty days. But the gains over the last month wer

Simply Wall StMay 6 18:30 ET

Jiangxi Fushine Pharmaceutical (SZSE:300497) Is Carrying A Fair Bit Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StApr 30 02:34 ET

Fuxiang Pharmaceutical (300497.SZ): Net profit of 1.468,500 yuan for the first quarter reversed the year-on-year loss

Gelonghui, April 28 | Fuxiang Pharmaceutical (300497.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 340 million yuan, a year-on-year decrease of 14.45%; net profit attributable to shareholders of listed companies was 1.468,500 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 10.21 million yuan; basic earnings per share.

Gelonghui FinanceApr 28 04:34 ET